enzastaurin has been researched along with Astrocytoma, Grade IV in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Combs, SE; Hartmann, C; Moreau-Donnet, V; Platten, M; Shei, P; Steinbach, JP; Stoffregen, C; von Deimling, A; Wenz, F; Wick, W | 1 |
| Cartron, PF; Cheray, M; Nadaradjane, A; Pacaud, R; Vallette, FM | 1 |
| Butowski, N; Cha, S; Chang, S; Crane, J; Kadambi, AK; Li, Y; Molinaro, A; Nelson, SJ; Olson, M; Park, I; Roy, R | 1 |
| Buckner, JC; Galanis, E | 1 |
| Carpentier, AF; Chamberlain, MC; Cher, LM; Fine, HA; Hong, S; Liepa, AM; Mason, W; Musib, L; Puduvalli, VK; Thornton, DE; van den Bent, MJ; Weller, M; Wick, W | 1 |
| Butowski, N; Chang, SM; Hristova-Kazmierski, M; Lamborn, KR; Musib, L; Nicol, SJ; Parvataneni, R; Polley, MY; Prados, MD; Thornton, DE | 1 |
| Butowski, NA; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Nelson, SJ; Polley, MY | 1 |
| Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S | 1 |
| Decker, R; Gharib, M; Gorlia, T; Lacombe, D; Lai, C; Rampling, R; Sanson, M; Stoffregen, C; Taal, W; van den Bent, MJ | 1 |
| Butowski, N; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Molinaro, AM; Nelson, SJ | 1 |
| Bailey, SN; Banks, C; Brown, TJ; Campbell, RM; Capen, A; Geeganage, S; Goode, R; Graff, JR; Hanna, KR; Huss, KL; Iversen, PW; Konicek, BW; Lewis, JE; Lynch, RL; McNulty, AM; Musib, L; Neubauer, BL; Sams, L; Thornton, D | 1 |
| Kondo, S; Kondo, Y | 1 |
5 trial(s) available for enzastaurin and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Survival Rate; Tumor Suppressor Proteins | 2013 |
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Glioblastoma; Humans; Indoles; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local | 2010 |
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Male; Middle Aged; Temozolomide; Young Adult | 2010 |
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Case-Control Studies; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dacarbazine; DNA Methylation; DNA, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Gliosarcoma; Humans; Immunoenzyme Techniques; Indoles; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymerase Chain Reaction; Prospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2011 |
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Temozolomide; Young Adult | 2012 |
7 other study(ies) available for enzastaurin and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Glioblastoma; Histones; Humans; Indoles; Male; Middle Aged; Organophosphates; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrazoles; Pyrimidines; Quinazolines; Temozolomide | 2015 |
Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choline; Cohort Studies; Combined Modality Therapy; Creatine; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Grading; Prognosis; Radiotherapy, Conformal; Survival Rate; Temozolomide; Tumor Burden | 2017 |
Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize.
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; Glioblastoma; Humans; Indoles; Protein Kinase C; Protein Kinase C beta; Recurrence; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Perfusion; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide | 2013 |
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Topics: Animals; Apoptosis; Cell Growth Processes; Colonic Neoplasms; Female; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HCT116 Cells; Humans; Indoles; Male; Mice; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
American Association for Cancer Research--97th annual meeting.
Topics: Adenine; Animals; Antineoplastic Agents; Benzoquinones; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Neoplasms, Experimental; Organophosphonates; Protein Kinase C; Protein Kinase Inhibitors; Signal Transduction; Topotecan; Tyrphostins | 2006 |